C3L-02349
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 81.0403833
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.420
- CHOLESTEROL_HOMEOSTASIS+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- XENOBIOTIC_METABOLISM+0.350
- FATTY_ACID_METABOLISM+0.340
- MYC_TARGETS_V2+0.340
- PEROXISOME+0.330
- MTORC1_SIGNALING+0.310
- MYC_TARGETS_V1+0.260
- ADIPOGENESIS+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- TGF_BETA_SIGNALING-0.470
- ANGIOGENESIS-0.450
- TNFA_SIGNALING_VIA_NFKB-0.420
- INFLAMMATORY_RESPONSE-0.310
- IL6_JAK_STAT3_SIGNALING-0.290
- KRAS_SIGNALING_UP-0.290
- PROTEIN_SECRETION-0.250
- UV_RESPONSE_DN-0.250
- INTERFERON_ALPHA_RESPONSE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.860 |
| 2 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.849 |
| 3 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.832 |
| 4 | TCGA-BH-A0E0-01A-11R-A056-07 | — | E | 0.827 |
| 5 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.826 |
| 6 | ERR2278847 | — | — | 0.824 |
| 7 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.823 |
| 8 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.823 |
| 9 | SRR6013549 | — | cohortSQ2 | 0.823 |
| 10 | ERR2278860 | — | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.350 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| PEROXISOME | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |